Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 14/20 | 1.00 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931255 | 0.88 | PTGES (1.00) | PTGESFFAR2PPARG | |
| SCHEMBL9931451 | 0.82 | PTGES (1.00) | PTGESFFAR2 | |
| SCHEMBL9931538 | 0.76 | PTGES (1.00) | PTGESFFAR2 | |
| SCHEMBL13024046 | 0.69 | FFAR2 (0.58) | PTGESFFAR2 | |
| SCHEMBL9960827 | 0.69 | PTGES (0.73) | PTGESFFAR2 | |
| Ly-3031207 SCHEMBL9931208 | 0.67 | PTGES (1.00) | PTGES | |
| SCHEMBL9975642 | 0.67 | PTGES (1.00) | PTGESFFAR2 | |
| SCHEMBL9959252 | 0.66 | PTGES (0.67) | PTGESFFAR2 | |
| SCHEMBL9931625 | 0.66 | PTGES (0.71) | PTGESPPARG | |
| SCHEMBL13380072 | 0.66 | FPR2 (0.50) | PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252831-B2 | Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252831-B2 | Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252831-B2 | Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120157506-A1 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157506-A1 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157506-A1 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157506-A1 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis | ARG2, HDAC6, COL2A1 | PTGES 550/4885FFAR2 1056/4885NPC1 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.